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The Nrf2 Activator (DMF) and 
Covid-19: Is there a Possible Role?
Saif M. Hassan1, Mahmood J. Jawad1, Salam W. Ahjel1, Ram B. Singh3, Jaipaul 
Singh4, Samir Mohamed Awad5, Najah R. Hadi2
ABSTRACT
Introduction: COVID-19 is a new viral illness that can affect the lungs and airways with lethal 
consequences leading to the death of the patients. The ACE2 receptors were widely disturbed 
among body tissues such as lung, kidney, small intestine, heart, and others in different per-
cent and considered a target for the nCOVID-19 virus. S-protein of the virus was binding to 
ACE2 receptors caused downregulation of endogenous anti-viral mediators, upregulation of 
NF-κB pathway, ROS and pro-apoptotic protein. Nrf2 was a transcription factor that’s play a 
role in generation of anti-oxidant enzymes. Aim: To describe and establish role of Nrf2 acti-
vators for treatment COVID-19 positive patients. Methods: We used method of analysis of the 
published papers with described studies about COVID-19 connected with pharmacological 
issues and aspects which are included in global fighting against COVID-19 infection, and how 
using DMF (Nrf2 activator) in clinical trial for nCOVID-19 produce positive effects in patients 
for reduce lung alveolar cells damage. Results: we are found that Nrf2 activators an import-
ant medication that’s have a role in reduce viral pathogenesis via inhibit virus entry through 
induce SPLI gene expression as well as inhibit TRMPSS2, upregulation of ACE2 that’s make 
a competition with the virus on binding site, induce gene expression of anti-viral mediators 
such as RIG-1 and INFs, induce anti-oxidant enzymes, also they have a role in inhibit NF-κB 
pathway, inhibit both apoptosis proteins and gene expression of TLRs. Conclusion: We are 
concluded that use DMF (Nrf2 activator) in clinical trial for nCOVID-19 positive patients to 
reduce lung alveolar cells damage.
Keywords: nCOVID-19, Nrf2 activators, ACE2, RIG-1, NF-κB and ROS.
1. INTRODUCTION
Corona virus diseases 19 (COVID 
19) has become a public health prob-
lem and its prevalence varies from 
country to country but it is present 
in 195 countries of the world. The 
risk of death from COVID-19 var-
ies from 1% in Germany to 11% in 
Italy indicating high fatality among 
subjects above 60 years (1). In hu-
mans, Transmembrane serine prote-
ase (TMPRSS2) is a protease under 
transmembrane serine protease fam-
ily, TMPRSS2 was disturbed widely 
in the upper airways, bronchi, and 
lung. TMPRSS2 was cleave corona-
virus fusion glycoproteins, the spike 
protein, such as severe acute respira-
tory syndrome-related coronavirus 
(SARS-CoV) as well as Middle East 
respiratory syndrome-related coro-
navirus (MERS-CoV) (2) facilitated 
entry into the host cell after bind-
ing to ACE2 receptor that’s make 
the virus entry to increased 2.6-fold 
in the presence of TMPRSS2, in the 
absence of TMPRSS2, the entry was 
decreased five-fold in absent it and 
this is accompanied by a nine-fold 
increase of the levels of the RNA and 
SARS-CoV in cells, expressing active 
TMPRSS2 compared to those cells 
with inactive TMPRSS2 (3). It is now 
known that ACE2 expression in the 
lung tissues of Asian population is 
much higher than white Caucasians 
and African-American (4). ACE2 is 
a carboxypeptidase which convert 
Ang I to angiotensin (1–9) and Ang 
II to angiotensin (1–7). Recent stud-
ies and analyses indicate SARS-coro-
navirus (SARS-CoV) and the novel 
coronavirus (2019-nCoV) have been 
target the angiotensin-convert-
ing enzyme 2 via spike proteins in 
the receptor-binding domain that 
maintains van der Waals forces and 
also showed that 2019-nCoV recep-
tor-binding domain (RBD) stronger 
than SARS-CoV due to glutamine 
residue 479 can recognized lysine 31 
on the human ACE2 receptor that 
2019-nCoV to transmit from person 
to person (6, 7). After entering of the 
virus to the cells, begin the host de-
fense mechanisms such as Retinoic 
acid-Inducible Gene I (RIG-I)-like 
receptors (RLRs) was directly recog-
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nizes and binds to virus, then ubiquitin 
by the E3 ligase leading to the phos-
phorylation and activation of NF-κB, 
In turn, this lead to the production of 
IFN-β which has antiviral activity (8). 
The N protein of SARS-CoV has been 
inhibits the synthesis of RIG-I ubiquiti-
nation and IFN-β (9, 10). ACE2 protein 
was downregulated during SARS-CoV 
infection that lead to lung injury due 
to ACE2 activity has negative regula-
tory effect on RAS in protection of the 
lung from injury (11) and ACE2 down 
regulation can also enhance NF–κB 
phosphorylation and further degrades 
a number of processes including IκBα 
protein, translocation, DNA bind-
ing, gene expression of pro-apoptotic 
proteins and cycline D1. As a result, 
pro-inflammatory cytokines such as 
IL-8 and IL-6 cytokines are secreted in 
large quantities. IL-8 and IL-6, in turn, 
stimulate monocytes, macrophages, 
NK, neutrophil and also monocyte mi-
gration to the site of the infection (12). 
Ang II has a proinflammatory proper-
ties via enhance NF-κB gene expression 
while ACE2 has an anti-inflammatory 
action by counteracting the actions of 
Ang II apoptosis and IL–1β and TNF–α secretion atten-
uated by ACE2 overexpression (13). One of the major 
pathogenic mechanisms for virus-induced inflammatory 
and tissue injury was generation of free radicals. Oxida-
tive stress was induced after viruses entering the host cell 
to facilitate their replication (14, 15) On other hand in-
crease ACE2 level may competitive with 2019-nCoV on 
binding (16). In a study by Li F et. al (2005) show that 
ACE2 was injection in a soluble form can slowdown en-
tering of viral into host cells (7). Similarly, Zhang R et. 
al show that ACE2 has protect the lung from injury (17) 
(Figure 1).
2. AIM
The aim of the study was to describe role of Nrf2 acti-
vators for treatment COVID-19 positive patients.
3. METHODS
We used method of analysis of the published papers 
with described studies about COVID-19 connected 
with pharmacological issues and aspects which are in-
cluded in global fighting against COVID-19 infection, 
and how using DMF (Nrf2 activator) in clinical trial for 
nCOVID-19 produce positive effects in patients for re-
duce lung alveolar cells damage.
4. RESULTS
Antiviral activity of Nrf2 activators
Nrf2 is a member of the cap‘n’collar (CNC) basic-leu-
cine-zipper transcription-factor, Nrf2 is considered as 
a master regulator of oxidative stress through enhance 
expression of anti-oxidant genes of glutathione and thi-
oredoxin-antioxidant systems and also Aldo-keto reduc-
tase, and NAD (P) H quinine-oxide-reductase-1, HO-1, 
NQO-1, SODs, GPx, GSTs, GCL, CAT, TRX Nrf2 system 
has anti-inflammatory, anti-apoptotic, and anti-oxidant 
through different pathways (18, 19). Nrf2 is a member 
of the CNC family which includes AP-1, NFE-2, Nrf-1, 
Nrf-2, Nrf-3, Bach-1 and -2, small-Mafs, and CREB/ATF 
and it can be divided into seven domains called Nrf2–
ECH-homology (Neh) domains Neh-1 to Neh-7 (20) 
(Figure 2).
Inhibit virus penetration
Nrf2 activators can increased anti-proteases secre-
tion such as the secretory leukocyte protease inhibitor 
(SLPI) that inhibit serine protease activity, It can also 
protect target cell against viral infection by binding to 
its promoter and thus decreases TMPRSS2 expression 
(21), Hence, these activators can protect the cell against 
the entry of viruses into respiratory epithelial cells and 
thereby decreasing their replication (Figure 3). In a study 
by Iizuka et al. 2005, they found that SLPI not express in 
Nrf2-knockout mice that made the cells predisposed to 
inflammation by disturb protease/anti-protease balance, 
and they found SLPI gene expression was increase when 
activation of Nrf2 not only by the anti-oxidant effect, but 
by maintenance the protease/anti-protease balance (22). 
Similarly, Ling JX et al. 2012 showed that oral adminis-
tration of EGCG (Nrf2 activator) improved the survival 
by decreased the entry and replication of viral pneumo-
nia in the lungs in same equivalent to oral administration 
of oseltamivir.
Figure 1. Schematic diagram showing the pathogenesis of nCOVID-19 induce inflammation and 
cell damage via activation of NF-κB pathway and generation of ROS that lead to production of 
pro-inflammatory cytokines as well as cause secondary bacterial infection (17)
Figure 2. Diagram showing the structure of human Nrf-2 (20)
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Alveolar protection role
Alveolar epithelial type II cells were considered the 
more abundant cells in lung that express ACE2 which 
about 83% (23). Moreover, ACE2 protein is expressed in 
an abundant quantity on the apical airway epithelia and 
moreover, the expression ACE2 is more likely to be link 
with the epithelia differentiation. As such, well differen-
tiated cells are more likely to be infected by SARS-CoV 
(24). Nrf2 was prevent the alteration in lung injury by in-
creased level of ACE2 and expression of AT2R. On other 
hand, Nrf2 was decreased serum levels of Ang II and the 
expression of AT1R by suppressed oxidative stress, in-
flammation, and fibrosis induced by Ang II/AT1R axis 
(25) Nrf2 was play a role in induction of host defense 
mechanism through induction of interferon gene expres-
sion that have antiviral activity. In their study, Kesic et 
al. show that Nrf2 activators induced the expression of 
antiviral genes of RIG-I and IFN-β (26).
Anti-inflammatory and anti-apoptotic activities
Nrf2 pathway inhibits the NF-κB activity through the 
degradation of IKKβ by ubiquitination and induction 
gene transcription when NF-κB react with Nrf2 tran-
scriptional-CBP. Activation of the Nrf2- dependent an-
ti-oxidant genes suppress the production of inflamma-
tory factors such as TNF-α, IL-6, MCP-1, MIP2 (27) in 
addition to downregulation of the selectins and VCAM-
1, adhesion molecules (28). Nrf2 was 
play an important role in expression 
of TLRs through inhibit expression of 
these receptors (29). Li et al. observed 
that Nrf2 knockout mice increases the 
expression of the TLR4 as compared 
with the wild type mice (30). Yanzhe 
Wang et al. (2018) observed that Nrf2 
activator treatment decreases number 
TLR-positive cells as compared with 
control when measured by immuno-
histochemistry (31).
The activation of Nrf2 can improve 
phagocytosis and clearance by alveolar 
macrophages through a mechanism 
that is independent of the intracellu-
lar-antioxidant glutathione (32). Nrf2 is 
the major regulatory system of GSH via 
controlling and modulatory release of 
γ-glutamyl cysteine ligase (33). Nrf2 in-
duces production a number of anti-ox-
idant enzymes such as NQO1, HO-1, 
SODs, Grx1, and Trx1 (34) and reduced 
upregulated expression of HO-1, Bcl-2/
Bax, decreased expression and activity 
of caspases 3, 9 (35).
Dimethyl fumarate (DMF)
DMF a fumarate ester, is a recently 
FDA approved drug for the treatment 
of multiple sclerosis (MS) and psoria-
sis under market name Ticfedra (36). 
DMF is a potent anti-oxidant and an-
ti-inflammatory agent via inhibits the 
NF-κB pathway through binding and 
activation of the IKKβ at Cys-179. This binding inhibits 
the release of NF-κB wfrom its complex (NF-κB-IκB) in 
the cytoplasm, thereby inhibiting downstream pro-in-
flammatory signaling pathways (37). In addition, it’s 
modulation of the glutathione system and enhancement 
of cellular response to oxidative stress (38). The molec-
ular mechanism of action of the DMF was activation of 
Nrf2 and blocking the activity of NF-κB thereby plays 
an important role in the suppress of inflammation. In 
the absence of DMF, Nrf2 binds to Keap1 which makes 
it subjected to ubiquitination. DMF was disrupt Keap1-
Nrf2 complex at its cysteine residues causes the release of 
Nrf2 and translocation of Nrf2 to the nucleus (37). DMF 
is a potent inhibitor of the NF-κB pathway through bind-
ing and activation of the IKKβ at Cys-179. This binding 
inhibits the release of NF-κB from its complex (NF-κB-
IκB) in the cytoplasm, thereby inhibiting downstream 
pro-inflammatory signaling pathways (38) (Figure 4).
5. CONCLUSION
In conclusion and from the supporting literature re-
view, it is tempting to suggest that DMF may be able to 
inhibit the entry of nCOVID-19 into the alveolar cells 
of the lungs via an increase in anti-protease (SPLI) and 
a concurrent decrease in the protease protein (TRM-
PSS2). Furthermore, DMF can decrease inflammation 
Figure 3. Nrf2 activator wasinducing gene expression of anti-oxidant enzymes and SLPI anti-
protease protein in addition to inhibit gene expression of TMRPSS2, therefore inhibit virus entry 
and replication (26)
Figure 4. Schematic flow diagram showing the proposed mechanism (s) of action of DMF (38)
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and ROS through the inhibition of NF-kB by inducing 
anti-oxidant enzymes thereby down regulating TLRs 
and increasing anti-viral mediators such as RIG-1 and 
INFs via the induction of gene expression, an increase 
ACE2 enzyme and a decrease in AT1R. As such, DMF 
should be recommended in clinical trials in patients with 
nCOVID-19.
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